TAMPA, Fla. and LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today ...
Patients with RAS G12D non-small cell lung cancer remain a population with a significant unmet medical need for targeted therapeutic options,” said Jonathan Riess M.D., medical director of thoracic ...
CINCINNATI (WKRC) — Researchers are conducting a groundbreaking trial that could revolutionize the way the body fights cancer, particularly for those living with pancreatic cancer. This trial is ...
Daraxonrasib improved survival in metastatic pancreatic cancer in Phase III, signaling meaningful progress for therapies targeting RAS‑driven disease.
BridgeBio Oncology Therapeutics, a company working to advance the field of therapies addressing a validated but elusive group of cancer targets, has reached a deal to go public in a SPAC merger that ...
Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 303, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results